Milestone Pharmaceuticals Financial Results
Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.
- Term
- Q3 2026
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer